
    
      This is a Phase 1, open-label, non-randomized, dose escalation study of TAS-119 evaluating
      the safety, tolerability, PK, pharmacogenomics, pharmacodynamics, and preliminary antitumour
      activity in patients with advanced and unresectable solid tumours. The study will evaluate
      TAS-119 monotherapy, employing two sequential phases.

        -  A Dose Escalation Phase

        -  An Expansion Phase
    
  